Scleroderma Research Foundation
Balance Sheet
Fiscal Year Start:
Jan 1
Assets in 2024 (Year End)
$32,999,784
Cash & Equivalents
54%
Investments
40%
Receivables (Non-Related)
4%
Other Assets
<1%
Prepaid Expenses
<1%
Property, Plant, & Equipment (net)
<1%
Related-Party Receivables
0%
Inventories
0%
Liabilities in 2024 (Year End)
$18,916,787
Other Liabilities
58%
Payables & Accruals
38%
Grants Payable
3%
Deferred Revenue
<1%
Tax-Exempt Bond Liabilities
0%
Custodial & Escrow Liabilities
0%
Notes Payable / Debt (Non-Related)
0%
Related-Party Payables
0%
Assets
2023
2024
Change
Cash & Equivalents
$3,933,724
$17,941,839
+356%
Receivables (Non-Related)
$1,071,849
$1,269,620
+18%
Related-Party Receivables
$0
$0
-
Inventories
$0
$0
-
Prepaid Expenses
$56,574
$203,741
+260%
Investments
$13,488,695
$13,267,844
-2%
Property, Plant, & Equipment (net)
$31,629
$19,535
-38%
Other Assets
$72,277
$297,205
+311%
Total Assets
$18,654,748
$32,999,784
+77%
Liabilities
2023
2024
Change
Payables & Accruals
$2,842,768
$7,245,249
+155%
Grants Payable
-
$500,000
-
Deferred Revenue
$300,849
$156,432
-48%
Tax-Exempt Bond Liabilities
-
-
-
Custodial & Escrow Liabilities
-
-
-
Notes Payable / Debt (Non-Related)
-
-
-
Related-Party Payables
-
-
-
Other Liabilities
$3,978,774
$11,015,106
+177%
Total Liabilities
$7,122,391
$18,916,787
+166%
Net assets
2023
2024
Change
Restricted Net Assets
$1,047
$259,000
+24637%
Unrestricted Net Assets
$11,531,310
$13,823,997
+20%
Net assets
2023
2024
Change
Net assets
+$11,532,357
+$14,082,997
+22%
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)